CTOs on the Move

CareAllies

www.careallies.com

 
CareAllies works side-by-side with health care providers to help improve the quality, value and experience of care for their patients, to make health care better for everyone. Our aim: To support doctor-patient-community engagement that enhances the quality and affordability of care. It`s how physicians and health systems will deliver sustainable value-based care and continue to thrive in the future.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Comphealth Associates

Comphealth Associates is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centennial House

Centennial House is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paradigm Biodevices

Paradigm Biodevices is a Rockland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sebela Pharmaceuticals

Sebela Pharmaceuticals is a growth-oriented organization focused on providing high quality branded prescription pharmaceutical products to patients and providers within the healthcare community. Members of our team are focused on results and operate with the highest degree of ethics and integrity.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.